GlassScriptPhysician profile
Ronald Rothenberg
NPI 1487634986
$5,110.28
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $842 · 2021: $1,565 · 2022: $909 · 2023: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $961.93 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $512.90 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.23 | 2019-2022 | |
| Amarin Pharma, INC. | $405.45 | 2019-2022 | |
| Astellas Pharma US INC | $363.28 | 2019-2023 | Veozah |
| Abbvie INC. | $359.80 | 2021-2023 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $245.44 | 2019-2023 | Breztri |
| Pfizer INC. | $200.83 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $197.47 | 2019-2021 | |
| Lilly USA, LLC | $167.64 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $156.53 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $139.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $113.02 | 2019-2022 | |
| Amgen INC. | $111.18 | 2019-2022 | |
| Indivior INC. | $105.25 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $89.77 | 2021 | |
| Allergan, INC. | $75.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.18 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $60.87 | 2019-2022 | |
| Dexcom, INC. | $55.57 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.73 | 2022 | |
| Circassia INC. | $25.27 | 2020 | |
| Abbott Laboratories | $23.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.96 | 2022 | |
| Philips North America LLC | $18.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2023 | |
| Shire North American Group INC | $16.25 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.10 | 2022 | |
| Sanofi Pasteur INC. | $14.93 | 2020 | |
| Inari Medical, INC. | $14.86 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $12.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Rothenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.